Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Roche's Actemra Fails In Phase III COVID Study

Plus: Favipiravir Market Heating Up In India

Executive Summary

Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints. 

You may also be interested in...



Coronavirus Update: South Korean Nod For AZ/Oxford Vaccine, Actemra Progesses In Japan

South Korea approves AstraZeneca’s COVID-19 Vaccine, while Actemra moves forward in Japan after local study results.

Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations

Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.

AI Can Find Many Drugs To Repurpose For COVID-19, But Real-World Results Mixed

A study presented at a recent MIT-sponsored conference used network medicine to uncover dozens of potential opportunities for existing drugs to be repurposed for COVID-19.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel